{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T12:50:00Z","timestamp":1761569400051,"version":"build-2065373602"},"reference-count":41,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007914","name":"The University of Texas Southwestern Medical Center","doi-asserted-by":"publisher","award":["P50CA196516"],"award-info":[{"award-number":["P50CA196516"]}],"id":[{"id":"10.13039\/100007914","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000861","name":"Burroughs Wellcome Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000861","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.clgc.2023.01.011","type":"journal-article","created":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T12:47:08Z","timestamp":1675255628000},"page":"497-506","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Life-threatening hemoptysis in patients with metastatic kidney cancer"],"prefix":"10.1016","volume":"21","author":[{"given":"Viral M.","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy","family":"Elias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1550-6349","authenticated-orcid":false,"given":"Annapoorani","family":"Asokan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akanksha","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alana","family":"Christie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Pedrosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsienchang","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Reznik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquibul","family":"Hannan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Timmerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8575-499X","authenticated-orcid":false,"given":"James","family":"Brugarolas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clgc.2023.01.011_bib0001","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.1016\/j.clgc.2023.01.011_bib0002","unstructured":"Institute NNC. Cancer Stat Facts: Kidney and Renal Pelvis Cancer. 2021 (https:\/\/seer.cancer.gov\/statfacts\/html\/kidrp.html)."},{"issue":"14","key":"10.1016\/j.clgc.2023.01.011_bib0003","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1016\/j.clgc.2023.01.011_bib0004","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1016\/j.clgc.2023.01.011_bib0005","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"14","key":"10.1016\/j.clgc.2023.01.011_bib0006","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1016\/j.clgc.2023.01.011_bib0007","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clgc.2023.01.011_bib0008","first-page":"737","article-title":"A systematic review of stereotactic radiotherapy ablation for primary renal cell carcinoma","volume":"110","author":"Siva","year":"2012","journal-title":"BJU International"},{"key":"10.1016\/j.clgc.2023.01.011_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctarc.2019.100161","article-title":"Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study","volume":"22","author":"Buti","year":"2020","journal-title":"Cancer Treatment and Research Communications"},{"issue":"6","key":"10.1016\/j.clgc.2023.01.011_bib0010","doi-asserted-by":"crossref","first-page":"e589","DOI":"10.1016\/j.prro.2015.05.004","article-title":"Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: Is RCC truly radioresistant?","volume":"5","author":"Amini","year":"2015","journal-title":"Practical Radiation Oncology"},{"issue":"18","key":"10.1016\/j.clgc.2023.01.011_bib0011","article-title":"Renal Cancer is Not Radioresistant: Slowly but Continuing Shrinkage of the Tumor After Stereotactic Body Radiation Therapy","volume":"1","author":"Funayama","year":"2019","journal-title":"Technology in Cancer Research & Treatment"},{"issue":"5","key":"10.1016\/j.clgc.2023.01.011_bib0012","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/PPO.0000000000000475","article-title":"The Reintroduction of Radiotherapy Into the Integrated Management of Kidney Cancer","volume":"26","author":"Dohopolski","year":"2020","journal-title":"Cancer Journal"},{"issue":"5","key":"10.1016\/j.clgc.2023.01.011_bib0013","article-title":"Stereotactic Ablative Radiation Therapy for Oligoprogressive Renal Cell Carcinoma","volume":"6","author":"Schoenhals","year":"2021","journal-title":"Adv Radiat Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2023.01.011_bib0014","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijrobp.2019.07.023","article-title":"Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer","volume":"105","author":"Zhang","year":"2019","journal-title":"International Journal of Radiation Oncology Biology Physics"},{"key":"10.1016\/j.clgc.2023.01.011_bib0015","article-title":"Stereotactic Ablative Radiation for Systemic Therapy-naive Oligometastatic Kidney Cancer","author":"Hannan","year":"2022","journal-title":"Eur Urol Oncol"},{"issue":"12","key":"10.1016\/j.clgc.2023.01.011_bib0016","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/S1470-2045(21)00528-3","article-title":"Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial","volume":"22","author":"Tang","year":"2021","journal-title":"Lancet Oncology"},{"key":"10.1016\/j.clgc.2023.01.011_bib0017","article-title":"Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer","author":"Hannan","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2023.01.011_bib0018","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.eururo.2021.07.026","article-title":"Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study","volume":"80","author":"Cheung","year":"2021","journal-title":"European Urology"},{"issue":"30","key":"10.1016\/j.clgc.2023.01.011_bib0019","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1200\/JCO.2006.07.5937","article-title":"Excessive Toxicity When Treating Central Tumors in a Phase II Study of Stereotactic Body Radiation Therapy for Medically Inoperable Early-Stage Lung Cancer","volume":"24","author":"Timmerman","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.clgc.2023.01.011_bib0020","doi-asserted-by":"crossref","DOI":"10.21037\/tro.2019.05.01","article-title":"Stereotactic ablative radiotherapy for central and ultra-central lung tumors","volume":"3","author":"Chaudhuri","year":"2019","journal-title":"Therapeutic Radiology and Oncology"},{"issue":"2","key":"10.1016\/j.clgc.2023.01.011_bib0021","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/j.prro.2018.11.005","article-title":"Tumor Control and Toxicity after SBRT for Ultracentral, Central, and Paramediastinal Lung Tumors","volume":"9","author":"Nguyen","year":"2019","journal-title":"Practical Radiation Oncology"},{"issue":"3","key":"10.1016\/j.clgc.2023.01.011_bib0022","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ijrobp.2008.11.042","article-title":"Stereotactic Body Radiation Therapy for Early-Stage Non\u2013Small-Cell Lung Carcinoma: Four-Year Results of a Prospective Phase II Study","volume":"75","author":"Fakiris","year":"2009","journal-title":"International Journal of Radiation Oncology Biology Physics"},{"issue":"4","key":"10.1016\/j.clgc.2023.01.011_bib0023","first-page":"4498","article-title":"Stereotactic body radiotherapy for centrally-located lung tumors with 56 Gy in seven fractions: A retrospective study","volume":"16","author":"Aoki","year":"2018","journal-title":"Oncology Letters"},{"issue":"3","key":"10.1016\/j.clgc.2023.01.011_bib0024","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.radonc.2009.03.005","article-title":"Central thoracic lesions treated with hypofractionated stereotactic body radiotherapy","volume":"91","author":"Milano","year":"2009","journal-title":"Radiotherapy and Oncology"},{"issue":"6","key":"10.1016\/j.clgc.2023.01.011_bib0025","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s11604-015-0423-4","article-title":"A case of severe hemoptysis after stereotactic body radiotherapy for peripherally located stage I non-small cell lung cancer","volume":"33","author":"Kimura","year":"2015","journal-title":"Japanese Journal of Radiology"},{"issue":"5","key":"10.1016\/j.clgc.2023.01.011_bib0026","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/jrr\/rrz044","article-title":"Stereotactic body radiotherapy for primary non-small cell lung cancer patients with clinical T3-4N0M0 (UICC 8th edition): outcomes and patterns of failure","volume":"60","author":"Narita","year":"2019","journal-title":"J Radiat Res"},{"issue":"4","key":"10.1016\/j.clgc.2023.01.011_bib0027","first-page":"2695","article-title":"Salvage stereotactic body radiotherapy for post-operative oligo-recurrence of non-small cell lung cancer: A single-institution analysis of 59 patients","volume":"19","author":"Aoki","year":"2020","journal-title":"Oncology Letters"},{"issue":"123","key":"10.1016\/j.clgc.2023.01.011_bib0028","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/cncr.30375","article-title":"Multi-institutional experience of stereotactic body radiotherapy for large (\u22655 centimeters) non-small cell lung tumors","volume":"15","author":"Verma","year":"2017","journal-title":"Cancer"},{"issue":"123","key":"10.1016\/j.clgc.2023.01.011_bib0029","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1002\/cncr.30693","article-title":"7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial","volume":"15","author":"Sun","year":"2017","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.clgc.2023.01.011_bib0030","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/JTO.0000000000000453","article-title":"Stereotactic ablative radiotherapy for centrally located early stage non-small-cell lung cancer: what we have learned","volume":"10","author":"Chang","year":"2015","journal-title":"Journal of Thoracic oncology"},{"issue":"1","key":"10.1016\/j.clgc.2023.01.011_bib0031","doi-asserted-by":"crossref","first-page":"48","DOI":"10.21037\/tlcr.2018.10.06","article-title":"The evolving toxicity profile of SBRT for lung cancer","volume":"8","author":"Thompson","year":"2018","journal-title":"Translational Lung Cancer Research"},{"issue":"7","key":"10.1016\/j.clgc.2023.01.011_bib0032","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jtho.2021.03.019","article-title":"The HILUS-Trial\u2014a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy","volume":"16","author":"Lindberg","year":"2021","journal-title":"Journal of Thoracic Oncology"},{"issue":"5","key":"10.1016\/j.clgc.2023.01.011_bib0033","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/PPO.0000000000000480","article-title":"The von Hippel-Lindau Tumor Suppressor Gene: Implications and Therapeutic Opportunities","volume":"26","author":"Elias","year":"2020","journal-title":"Cancer J"},{"issue":"4","key":"10.1016\/j.clgc.2023.01.011_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2021.12.018","article-title":"Stereotactic ablative radiation therapy for renal cell carcinoma with inferior vena cava tumor thrombus","volume":"40","author":"Freifeld","year":"2022","journal-title":"Urol Oncol"},{"issue":"6_suppl","key":"10.1016\/j.clgc.2023.01.011_bib0035","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1200\/JCO.2020.38.6_suppl.614","article-title":"Combination of dual immune checkpoint inhibition (ICI) with stereotactic radiation (SBRT) in metastatic renal cell carcinoma (mRCC) (RADVAX RCC)","volume":"38","author":"Hammers","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"24","key":"10.1016\/j.clgc.2023.01.011_bib0036","doi-asserted-by":"crossref","first-page":"6716","DOI":"10.1158\/1078-0432.CCR-21-2083","article-title":"Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma","volume":"27","author":"Hannan","year":"2021","journal-title":"Clin Cancer Research"},{"issue":"2","key":"10.1016\/j.clgc.2023.01.011_bib0037","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0720-048X(03)00209-2","article-title":"Endobronchial metastasis from renal cell carcinoma: CT findings in four patients","volume":"51","author":"Park","year":"2004","journal-title":"European Journal of Radiology"},{"issue":"1","key":"10.1016\/j.clgc.2023.01.011_bib0038","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/02841860310018053","article-title":"Endobronchial metastases from extrapulmonary solid tumors","volume":"43","author":"S\u00f8rensen","year":"2004","journal-title":"Acta Oncologica"},{"issue":"8","key":"10.1016\/j.clgc.2023.01.011_bib0039","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.canrad.2019.05.016","article-title":"Illustration of a fatal radiation-induced lung aneurysm: Is central lung stereotactic radiotherapy to be banned?","volume":"23","author":"Ledoux","year":"2019","journal-title":"Cancer Radiotherapie"},{"issue":"2","key":"10.1016\/j.clgc.2023.01.011_bib0040","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3390\/cancers7020820","article-title":"Complications from Stereotactic Body Radiotherapy for Lung Cancer","volume":"7","author":"Kang","year":"2015","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clgc.2023.01.011_bib0041","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3389\/fonc.2014.00151","article-title":"The potential role of respiratory motion management and image guidance in the reduction of severe toxicities following stereotactic ablative radiation therapy for patients with centrally located early stage non-small cell lung cancer or lung metastases","volume":"4","author":"Chi","year":"2014","journal-title":"Front Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767323000332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767323000332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:36:41Z","timestamp":1761565001000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767323000332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S1558767323000332"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2023.01.011","relation":{},"ISSN":["1558-7673"],"issn-type":[{"type":"print","value":"1558-7673"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Life-threatening hemoptysis in patients with metastatic kidney cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2023.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}